BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10973444)

  • 1. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).
    Moss RB; Giermakowska W; Wallace MR; Savary J; Jensen F; Carlo DJ
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):724-7. PubMed ID: 10973444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
    Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
    Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Savary JR; Jensen FC; Carlo DJ
    AIDS; 2000 Nov; 14(16):2475-8. PubMed ID: 11101057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.
    Leandersson AC; Gilljam G; Fredriksson M; Hinkula J; Alaeus A; Lidman K; Albert J; Bratt G; Sandström E; Wahren B
    J Virol; 2000 May; 74(10):4888-90. PubMed ID: 10775629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
    Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
    AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
    Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
    AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.
    Kalams SA; Buchbinder SP; Rosenberg ES; Billingsley JM; Colbert DS; Jones NG; Shea AK; Trocha AK; Walker BD
    J Virol; 1999 Aug; 73(8):6715-20. PubMed ID: 10400769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
    Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
    Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.
    Boyer JD; Cohen AD; Ugen KE; Edgeworth RL; Bennett M; Shah A; Schumann K; Nath B; Javadian A; Bagarazzi ML; Kim J; Weiner DB
    AIDS; 2000 Jul; 14(11):1515-22. PubMed ID: 10983638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
    Rosenberg ES; Billingsley JM; Caliendo AM; Boswell SL; Sax PE; Kalams SA; Walker BD
    Science; 1997 Nov; 278(5342):1447-50. PubMed ID: 9367954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Jensen FC; Maigetter RZ; Carlo DJ
    Clin Exp Immunol; 2001 May; 124(2):248-54. PubMed ID: 11422201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.
    Feeney ME; Draenert R; Roosevelt KA; Pelton SI; McIntosh K; Burchett SK; Mao C; Walker BD; Goulder PJ
    J Immunol; 2003 Dec; 171(12):6968-75. PubMed ID: 14662905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.